📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.

Summit Therapeutics Inc

Common Name
Summit Therapeutics
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
159
Ticker
SMMT
Exchange
NASDAQ/NMS
Description
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs, primarily in the realm of infectious diseases. The...

Summit Therapeutics's Financial Statements Preview

Below are the financial statements of Summit Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of USD
2024
2023
2022
Revenue
0a
0a
0.71a
Operating expenses
Research and development
-150.78a
-59.47a
-52a
Acquired in-process research and development
-15.01a
-520.92a
0a
General and administrative
-60.53a
-30.27a
-26.74a
Impairment of intangible assets
0a
0a
-8.47a
Total operating expenses
-226.31a
-610.65a
-87.21a
Other operating income, net
0.31a
1a
14.42a
Operating loss
-226a
-609.65a
-72.09a
Other income (expense), net
13.37a
11.18a
-2.29a
Interest expense
-8.69a
-16.46a
-4.4a
Net loss
-221.32a
-614.93a
-78.78a
Download Data

Verified Sources Behind Summit Therapeutics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Summit Therapeutics’s data sources below and access millions more through our Disclosure Search.

a. Summit Therapeutics's 10-K 2024
a. Summit Therapeutics's 10-K 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?